Patent assignee · FR · COMPANY

GENETHON

54Patents
53Active
54Granted
53Portfolio score

Filing activity: Jul 16, 2007 → Aug 1, 2023 · 5 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US10752898B2 Effective gene therapy tools for dystrophin exon 53 skipping Chemistry; Metallurgy 31 Active
US10208318B2 CNS gene delivery using peripheral administration of AAV vectors Chemistry; Metallurgy 27 Active
US9926574B2 Widespread gene delivery to motor neurons using peripheral injection of AAV vectors Chemistry; Metallurgy 21 Active
US10166272B2 Efficient systemic treatment of dystrophic muscle pathologies Chemistry; Metallurgy 11 Active
US9487782B2 Methods for the treatment of leber congenital amaurosis Emerging Cross-Sectional Technologies 7 Active
US8957044B2 Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) Chemistry; Metallurgy 6 Active
US9415120B2 Systemic gene replacement therapy for treatment of X-linked MyoTubular Myopathy (XLMTM) Chemistry; Metallurgy 5 Active
US9114161B2 Widespread gene delivery to the retina using systemic administration of AAV vectors Chemistry; Metallurgy 4 Active
US10465169B2 Method for purifying enveloped viruses or viral vectors Chemistry; Metallurgy 3 Active
US9895426B2 Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) Chemistry; Metallurgy 3 Active
US11421211B2 Acid-alpha glucosidase variants and uses thereof Chemistry; Metallurgy 3 Active
US10125352B2 Method for producing enveloped viruses Chemistry; Metallurgy 3 Active
US9839677B2 Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) Chemistry; Metallurgy 3 Active
US9012425B2 Methods for the treatment of Leber congenital amaurosis Emerging Cross-Sectional Technologies 3 Active
US11339406B2 Acid-alpha glucosidase variants and uses thereof Chemistry; Metallurgy 3 Active
US9862934B2 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions Chemistry; Metallurgy 2 Active
US9777272B2 Methods for the treatment of Leber congenital amaurosis Emerging Cross-Sectional Technologies 2 Active
US10786546B2 Efficient systemic treatment of dystrophic muscle pathologies Chemistry; Metallurgy 2 Active
US10471132B2 Treatment of hyperbilirubinemia Chemistry; Metallurgy 2 Active
US8993317B2 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions Chemistry; Metallurgy 1 Active
US11564977B2 Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) Chemistry; Metallurgy 1 Active
US10017783B2 Baculovirus system for the expression of a gene therapy vector Chemistry; Metallurgy 1 Active
US10597654B2 Methods for the treatment of Leber congenital amaurosis Emerging Cross-Sectional Technologies 1 Active
US9933438B2 Method for diagnosing muscular dystrophy Physics 1 Active
US10736945B2 Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) General 0 Revoked

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.